This startup wants to build a needle-free CGM using nanotechnology
Graphwear recently raised $20.5 million, which it plans to use to develop a CGM that uses nanotechnology to measure blood glucose levels.
Graphwear recently raised $20.5 million, which it plans to use to develop a CGM that uses nanotechnology to measure blood glucose levels.
The latest round of funding, led by Chinese investors, brings the total amount of money raised by the company, co-founded by CRISPR pioneer Jennifer Doudna, to more than $70 million.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company said it would use the funding to expand its single-cell DNA sequencing platform into CRISPR applications and global markets.
The company plans to use blockchain and other technologies to develop the genomic data marketplace, under a partnership with Veritas Genetics.